SEC Filing Intelligence
Biotech BD & Licensing Events
Classified 8-K events from SEC EDGAR: licensing agreements, strategic alternatives, M&A signals, and financing activity. Tagged by deal type and linked to company identifiers. Updated 3× daily from primary filings.
Request dataset →Live Sample
What the data looks like
Live data from our pipeline.
Arvinas, Inc. announced FDA approval for VEPPANU (vepdegestrant) for the treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, following at least one line of endocrine-based therapy. This marks the first FDA-approved PROteolysis Targeting Chimera (PROTAC) protein degrader. The approval, received ahead of the PDUFA date, triggered a $50.0 million development milestone payment from its collaborator, Pfizer Inc.
Replimune Group, Inc. announced receipt of a second Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec). The BLA sought approval for RP1 in combination with nivolumab for the treatment of advanced melanoma.
Genprex, Inc. announced that the Israel Patent Office granted a patent for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for use in combination with PD-1 antibodies for cancer treatment. This expands Genprex's intellectual property portfolio globally, building on existing patents in major markets. Reqorsa is initially being developed for lung cancer, with preclinical studies showing complementarity with targeted drugs and immunotherapies.
Cue Biopharma entered into an exclusive global (excluding Greater China) license agreement with Ascendant Health Sciences Ltd. for Ascendant-221 (formerly UB-221), an anti-IgE monoclonal antibody. Cue Biopharma will pay an upfront fee of $15.0 million, up to $676.5 million in potential development, regulatory, and commercial milestones, and tiered royalties on net sales.
Avalo Therapeutics, Inc. amended its merger agreement with AlmataBio, Inc. to restructure a contingent $15 million milestone payment. Avalo will pay $2.25 million immediately and has a 90-day option to pay an additional $5.125 million to fully satisfy the milestone, which was originally tied to the first patient dosed in a Phase 3 trial. If the option is not exercised, Avalo will pay $12.75 million upon the milestone event.
Live data from our pipeline. The structured export includes all fields listed below.
Use Cases
Who Uses This Data
Structured for direct analysis — no data cleaning, no manual joins required.
Healthcare Investment Banking
- ● Track licensing deal flow across therapeutic areas for pitch book and comp research
- ● Monitor strategic alternative announcements as M&A lead indicators
- ● Identify financing events and proceeds amounts for comparable transaction analysis
- ● Export structured deal data to populate precedent transaction databases
Corporate Business Development
- ● Monitor competitor licensing activity in your therapeutic area as it files
- ● Track strategic review announcements as potential partnership or acquisition signals
- ● Stay current on financing events that indicate pipeline funding status
- ● Cross-reference deal signals with clinical trial milestones for full pipeline context
What's Included
Data Fields
Primary Sources
- • SEC EDGAR 8-K filings (primary source)
- • 500+ tracked public biotech companies
- • Auto-classification by deal type and signal category
Fields Include
- • Company name, ticker, and SEC CIK
- • Filing date and 8-K accession number
- • Signal type (Licensing, Strategic Review, M&A, Financing, FDA Action, Clinical Data)
- • Deal excerpt auto-extracted from filing text
- • Counterparty name (where detectable)
- • Proceeds amount (financing events)
- • Link to original SEC EDGAR document
- • Linked trial count and phase distribution per company
Get the Data
Got it.
We'll follow up shortly.